clofibric acid has been researched along with Hypertriglyceridemia in 41 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a pilot study the therapeutic effect of 2 x 500 mg etofibrate (Lipo Merz retard) on lipids and lipoproteins, fibrinolytic activity and clinical parameters was studied for four weeks in hyperlipidemic patients suffering from arteriosclerosis obliterans (Fontaine stage II/III)." | 7.67 | [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. ( Basista, M; Bieroń, K; Czarnecka, H; Dembińska-Kieć, A; Grodzińska, L; Kedzior, A; Kostka-Trabka, E; Slawiński, M; Trabka, E; Zmuda, A, 1989) |
| "MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids." | 4.84 | Hypertriglyceridemia and cardiovascular risk reduction. ( Jacobson, TA; Miller, M; Schaefer, EJ, 2007) |
| " The aim of this work was to examine the effect of the PPARalpha agonist, ciprofibrate, on the CETP gene expression, in the presence and absence of apolipoprotein (apo) CIII induced hypertriglyceridemia, and its impact on the HDL metabolism." | 3.75 | Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver. ( Berti, JA; Bighetti, EJ; Casquero, AC; Oliveira, HC; Patrício, PR, 2009) |
| "In a pilot study the therapeutic effect of 2 x 500 mg etofibrate (Lipo Merz retard) on lipids and lipoproteins, fibrinolytic activity and clinical parameters was studied for four weeks in hyperlipidemic patients suffering from arteriosclerosis obliterans (Fontaine stage II/III)." | 3.67 | [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. ( Basista, M; Bieroń, K; Czarnecka, H; Dembińska-Kieć, A; Grodzińska, L; Kedzior, A; Kostka-Trabka, E; Slawiński, M; Trabka, E; Zmuda, A, 1989) |
| "Bezafibrate treatment was associated with significant risk reduction among coronary heart disease patients with elevated triglyceride levels that substantially reduced their triglyceride level with treatment." | 2.72 | Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy. ( Battler, A; Behar, S; Benderly, M; Boyko, V; Goldbourt, U; Goldenberg, I; Haim, M; Tanne, D, 2006) |
| "All patients with type 2 diabetes should reach an LDL cholesterol of <100 mg/dl, the very-high risk patients with both diabetes and coronary artery disease an LDL cholesterol <70 mg/dl." | 2.46 | [Lipid therapy in patients with diabetes]. ( Drexel, H; Saely, CH, 2010) |
| "Hypertriglyceridemia is a commonly encountered problem in primary care practice." | 2.44 | Bridging the gap in treatment options for patients with hypertriglyceridemia. ( Hays, R; Underberg, JA, 2007) |
| "Furthermore, severe hypertriglyceridemia is associated with an increased risk of acute pancreatitis, irrespective of its effect on risk of cardiovascular disease." | 2.44 | Hypertriglyceridemia: its etiology, effects and treatment. ( Al-Shali, KZ; Hegele, RA; Yuan, G, 2007) |
| "Hypertriglyceridemia is associated with an increased risk of cardiovascular events and acute pancreatitis." | 2.44 | Management of hypertriglyceridemia. ( Lanier, JB; Oh, RC, 2007) |
| "Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL." | 2.44 | Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. ( Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P, 2008) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "Niacin and fibrates have been shown in clinical trials to be effective as adjunctive therapy for these lipid abnormalities." | 1.35 | Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. ( Laitinen, D; Sullivan, JM; Toth, PP; Zarotsky, V, 2009) |
| "Monotherapy for the treatment of dyslipidemias is commonly insufficient to achieve all lipid targets recommended by current guidelines." | 1.33 | [Drug combinations: statins and fibrates]. ( Xavier, HT, 2005) |
| "The role of dyslipidemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidemic patients is an extremely important task in cardiovascular prevention." | 1.33 | [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care]. ( Ilyés, I; Jancsó, Z; Simay, A; Varga, Z, 2005) |
| "Ciprofibrate treatment (100 mg/day for 1 month) effected marked reductions in both total plasma LDL and apo B-100 levels (approximately 19% and approximately 23%, respectively)." | 1.29 | Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. ( Bruckert, E; Chapman, MJ; Dejager, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.44) | 18.7374 |
| 1990's | 5 (12.20) | 18.2507 |
| 2000's | 31 (75.61) | 29.6817 |
| 2010's | 4 (9.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Codario, RA | 1 |
| Underberg, JA | 1 |
| Hays, R | 1 |
| Gandotra, P | 1 |
| Miller, M | 2 |
| Prieur, X | 1 |
| Lesnik, P | 1 |
| Moreau, M | 1 |
| Rodríguez, JC | 1 |
| Doucet, C | 1 |
| Chapman, MJ | 2 |
| Huby, T | 1 |
| Toth, PP | 1 |
| Zarotsky, V | 1 |
| Sullivan, JM | 1 |
| Laitinen, D | 1 |
| Manfredi, R | 1 |
| Bighetti, EJ | 2 |
| Patrício, PR | 1 |
| Casquero, AC | 1 |
| Berti, JA | 1 |
| Oliveira, HC | 2 |
| Cohen, H | 1 |
| Bielorai, B | 1 |
| Harats, D | 1 |
| Toren, A | 1 |
| Pinhas-Hamiel, O | 1 |
| Saely, CH | 1 |
| Drexel, H | 1 |
| Jialal, I | 1 |
| Amess, W | 1 |
| Kaur, M | 1 |
| Jonkers, IJ | 2 |
| Smelt, AH | 2 |
| van der Laarse, A | 1 |
| Alberici, LC | 1 |
| de Faria, EC | 1 |
| Degaspari, GR | 1 |
| Souza, CT | 1 |
| Vercesi, AE | 1 |
| Dunbar, RL | 1 |
| Rader, DJ | 1 |
| Gouni-Berthold, I | 1 |
| Krone, W | 1 |
| Császár, A | 1 |
| Xavier, HT | 1 |
| Jancsó, Z | 1 |
| Varga, Z | 1 |
| Simay, A | 1 |
| Ilyés, I | 1 |
| Fruchart, JC | 1 |
| Duriez, P | 1 |
| Princen, HM | 1 |
| Kuipers, F | 1 |
| Romijn, JA | 1 |
| Boverhof, R | 1 |
| Masclee, AA | 1 |
| Stellaard, F | 1 |
| Geiss, HC | 1 |
| Parhofer, K | 1 |
| Haim, M | 1 |
| Benderly, M | 1 |
| Boyko, V | 1 |
| Goldenberg, I | 1 |
| Tanne, D | 1 |
| Battler, A | 1 |
| Goldbourt, U | 1 |
| Behar, S | 1 |
| Backes, JM | 1 |
| Gibson, CA | 1 |
| Ruisinger, JF | 1 |
| Moriarty, PM | 1 |
| Yuan, G | 1 |
| Al-Shali, KZ | 1 |
| Hegele, RA | 1 |
| Oh, RC | 1 |
| Lanier, JB | 1 |
| Jacobson, TA | 1 |
| Schaefer, EJ | 1 |
| Barter, PJ | 1 |
| Rye, KA | 1 |
| Brunzell, JD | 1 |
| Nagao, M | 1 |
| Oikawa, S | 1 |
| Yavasoglu, I | 1 |
| Kadikoylu, G | 1 |
| Bolaman, Z | 1 |
| Röggla, G | 1 |
| Fasan, M | 1 |
| Kapiotis, S | 1 |
| Holub, BJ | 1 |
| Leaf, DA | 1 |
| Raghavan, VA | 1 |
| Knopp, RH | 1 |
| Paramsothy, P | 1 |
| Atkinson, B | 1 |
| Dowdy, A | 1 |
| Bruckert, E | 1 |
| Dejager, S | 1 |
| Shepherd, J | 1 |
| Nagyová, A | 1 |
| Raslová, K | 1 |
| Ginter, E | 1 |
| Orth, M | 1 |
| Mayer, H | 1 |
| Halle, M | 1 |
| Luley, C | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Dembińska-Kieć, A | 1 |
| Kostka-Trabka, E | 1 |
| Grodzińska, L | 1 |
| Bieroń, K | 1 |
| Kedzior, A | 1 |
| Basista, M | 1 |
| Zmuda, A | 1 |
| Trabka, E | 1 |
| Slawiński, M | 1 |
| Czarnecka, H | 1 |
21 reviews available for clofibric acid and Hypertriglyceridemia
| Article | Year |
|---|---|
Bridging the gap in treatment options for patients with hypertriglyceridemia.
Topics: Adult; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Comorbidity; Drug Monitoring; Drug | 2007 |
The role of triglycerides in cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Humans; Hypertriglyceridemia; | 2008 |
[Lipid therapy in patients with diabetes].
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Dose-Response Relatio | 2010 |
Management of hypertriglyceridemia in the diabetic patient.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H | 2010 |
Hypertriglyceridemia: associated risks and effect of drug treatment.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Feeding Behavior; Fish Oil | 2001 |
Demystifying triglycerides: a practical approach for the clinician.
Topics: Arteriosclerosis; Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2005 |
Hypertriglyceridemia-why, when and how should it be treated?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Comorbidity; Evidence-Based Medic | 2005 |
Hypertriglyceridemia, the coronary heart disease risk marker "solved".
Topics: Apolipoprotein C-III; Apolipoproteins C; Clinical Trials as Topic; Clofibric Acid; Coronary Disease; | 2005 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
Fibrates: what have we learned in the past 40 years?
Topics: Clinical Trials as Topic; Clofibric Acid; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutar | 2007 |
Hypertriglyceridemia: its etiology, effects and treatment.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase | 2007 |
Management of hypertriglyceridemia.
Topics: Clofibric Acid; Diet; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrigly | 2007 |
Hypertriglyceridemia and cardiovascular risk reduction.
Topics: Atherosclerosis; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Fatty Acids, Omega-3; Hu | 2007 |
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hypertriglyceridemia; Hypolipidem | 2008 |
Clinical practice. Hypertriglyceridemia.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Clofibric Acid; Combined Modality Therapy; Diet Therapy | 2007 |
[Intervention for hypertriglyceridemia].
Topics: Aged; Bezafibrate; Clofibric Acid; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; | 2007 |
Chylomicronemia and the chylomicronemia syndrome: a practical approach to management.
Topics: Chylomicrons; Clofibric Acid; Diagnosis, Differential; Fatty Acids, Omega-3; Humans; Hypertriglyceri | 2008 |
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol | 2008 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Huma | 1993 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
4 trials available for clofibric acid and Hypertriglyceridemia
| Article | Year |
|---|---|
Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.
Topics: Bezafibrate; Bile Acids and Salts; Blood Glucose; Body Mass Index; Chenodeoxycholic Acid; Cholestero | 2006 |
Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
Topics: Aged; Bezafibrate; Clofibric Acid; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; | 2006 |
Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
Topics: Clofibric Acid; Copper; Diet, Fat-Restricted; Fibric Acids; Humans; Hypertriglyceridemia; Hypolipide | 1998 |
Hemostatic factors in hypertriglyceridemic men: effects of a fatty meal before and after triglyceride-lowering treatment with etofibrate.
Topics: Clofibric Acid; Dietary Fats; Double-Blind Method; Factor XII; Fasting; Hemostatics; Humans; Hypertr | 1999 |
16 other studies available for clofibric acid and Hypertriglyceridemia
| Article | Year |
|---|---|
Hypertriglyceridemia and cardiovascular disease management.
Topics: Adult; Cardiovascular Diseases; Clofibric Acid; Disease Management; Fatty Acids, Omega-3; Female; Hu | 2007 |
Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice.
Topics: Animals; Apolipoprotein A-V; Apolipoproteins; Apolipoproteins A; Base Sequence; Cell Line, Tumor; Cl | 2009 |
Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Drug Combinations; Female; Humans; | 2009 |
Management of hypertriglyceridaemia caused by combination antiretroviral therapy in HIV-infected patients: role of omega-3 polyunsaturated fatty acids at different dosages, compared with fibrates.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clofibric Acid; Fatty Acids, Omega-3; HIV In | 2010 |
Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.
Topics: Animals; Apolipoprotein C-III; Biological Transport; Cholesterol; Cholesterol Ester Transfer Protein | 2009 |
Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chi | 2010 |
Hypertriglyceridemia increases mitochondrial resting respiration and susceptibility to permeability transition.
Topics: Animals; Atractyloside; Cell Respiration; Clofibric Acid; Fibric Acids; Guanosine Diphosphate; Hyper | 2003 |
[Drug combinations: statins and fibrates].
Topics: Age Factors; Clofibric Acid; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Ge | 2005 |
[Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care].
Topics: Adult; Aged; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Continuity | 2005 |
[Diabetic dyslipoproteinemia].
Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 1; Diabet | 2006 |
Treating hypertriglyceridemia.
Topics: Adult; Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Heparin; Humans; Hydroxymethylglutar | 2007 |
Treating hypertriglyceridemia.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase | 2007 |
Treating hypertriglyceridemia.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Fatty Acids, Omega-3; Humans; Hydroxymethyl | 2007 |
First-line therapies for lowering triglyceride levels.
Topics: Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceride | 2008 |
Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Clofibric Acid; Fibric Acids; Humans; Hypercholester | 1993 |
[Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
Topics: Adult; Arteriosclerosis Obliterans; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; Hy | 1989 |